Provider Networks & CINs
Expert articles and analysis related to provider networks & cins.
AI Summary â Last 7 Days
Independent primary care aggregation remains a live VBC growth theme, with First Point ACOs marketing a 70/30 shared-savings model with zero downside risk to pull smaller practices into ACO participation while preserving independenceâan approach that could expand MSSP-style participation but may also intensify scrutiny of enablement fees, attribution, and savings distribution. At the same time, CMS is moving operationally to pay Qualifying Alternative Payment Model participants, requesting updated billing information so incentive payments can be disbursed, reinforcing that APM cash flow and administrative readiness remain material for provider networks and CINs. The broader Medicare policy backdrop is also shifting under the Trump administration as CMS advances CY2027/CY2026 Medicare Advantage and Part D technical changes, keeping payer-provider network strategy tightly linked to MA rules, risk adjustment, and value-based contracting mechanics. [First Point ACOs model](https://news.google.com/rss/articles/CBMi8gFBVV95cUxOc0l0Q005YUVrMWtpNkxVQlY2QUdGdXp4eUZRd3FnYkx2ZTZjNUVuck9iMi1CUFExN3Zjd2hfbFVTNDVLS1IyTWNuWlQxWWwtbGxaQy1MQTJtTDEwaU82UXZJb29Ucko0UW9PZ3Y5UjQ1Sml3cHM
Related Articles
MFP Effectuation and the SDRA: The Possibility of ASP Spirals in Competitive Drug Classes[
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
After a lower court rejected Teva's case last fall, a federal appeals court has revived part of the drugmakerâs lawsuit against Medicare negotiations. The DC Circuit Court ruled on Tuesday that Teva...
Response to Senate Finance Committee request for information on policies for lowering drug prices
Response to Senate Finance Committee request for information on policies for lowering drug prices  Brookings
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029
Comments on the Medicare Drug Price Negotiation Program proposed rule for IPAY 2029Â Â Brookings
Legislative Proposals Aim to Modify the 340B Program
STAT+: The White House declares âpromises made, promises keptâ on lowering drug prices. Nice try
In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative that doesn't reflect the full story.
Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting
List prices for brand-name drugs have declined significantly in 2026. But the reasons behind it may have more to do with a Biden-era law than any of the Trump administration's recent initiatives, expe...
AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program regulations
AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program regulations  American Hospital Association
A recent historic drop in drug prices is largely driven by market forces, Joyce explains
The post A recent historic drop in drug prices is largely driven by market forces, Joyce explains appeared first on USC Schaeffer.
Policy Options to Lower Drug Prices
Policy Options to Lower Drug Prices  Margolis Institute for Health Policy